Paul is trained as a pulmonary physician and has a long history in pharmaceutical research, development and management. He has held roles as CSO of Purdue Pharma, President of TransForm Pharmaceuticals (acquired by Johnson & Johnson), Vice-Chairman of Hypnion (acquired by Eli Lilly), and as Director of Promedior (acquired by Roche). Dr. Goldenheim received his AB from Harvard College magna cum laude with highest honors in biochemical sciences and his MD from Harvard Medical School.

President of One Equity Partners (“OEP”), a private equity firm that currently manages $7 billion for over 100 individual & institutional investors. In 1980, joined Citigroup Venture Capital (President 1994-2000) and in 2001, founded OEP which became the private equity business of JP Morgan Chase before it was spun out in early 2015. Dick has a BA in East Asian Studies from Harvard College (1975), an MBA from Harvard Business School (1980), was a member of the 1976 and 1980 U.S. Olympic Rowing Teams & was a world champion in 1974.

23 year managing member and General Partner of Manchester Management LLC, a family of investment funds that invests in public and private equities, primarily in the health care space. Previously Jeb worked at Highfields Capital and Media Group Investors in a variety of investment orientated roles. Jeb is the largest shareholder of Modular Medical, Inc. where he has been actively involved in developing Modular’s commercial go-to-market strategy since 2018. Jeb graduated from Brown University in 1997 with a B.A. in History, where he was a varsity rower and team captain.

Tim has amassed over 30 years’ experience in Pharma – across R&D, Business Development, GM & API roles. He previously held his own consultancy business, providing his expertise to industry and academic partners across pharmaceutical natural products & synthetic biology. Before this, he was Head of Australian Operations and R&D for Sun Pharmaceutical Industries controlled substances division. Tim has developed opiate alkaloid products from lab to market, co-authoring 3 Science papers on API biosynthesis along the way. He holds a BSc in Chemistry and from 2013-2015 was an Industrial Placement Fellow at the University of York, overseeing a range of new technology projects.

From 2013-2018, Jørgen served as Evolva’s Chief Scientific Officer, running a five-site R&D organization with the full complement of synthetic biology, from idea stage and bioinformatics over strain development to scale-up of upstream and downstream processes. Before that and since 2005, he has directed the activities of the Evolva Copenhagen laboratory. Previously he worked at Poalis Biotech, Carlsberg Laboratory, Danish Technical University and Aarhus University.

Esben has 14 years of experience within microbial production strain development, pathway discovery, and optimization. From 2011-2017, Esben served as Program Manager at Evolva, running several different strain development programs and has successfully brought projects from idea phase, over strain optimization to production. Previously he has worked at Poalis Biotech. He has a PhD in Molecular Biology/Pharmaceutical Science from University of Copenhagen.